{"id":391211,"date":"2015-12-11T00:00:00","date_gmt":"2015-12-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforem1515-biopharma-hospital-treated-infections-physician-payer-forum-brazil-mexico-2015\/"},"modified":"2026-03-31T09:02:38","modified_gmt":"2026-03-31T09:02:38","slug":"pforem1515-biopharma-hospital-treated-infections-physician-payer-forum-brazil-mexico-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforem1515-biopharma-hospital-treated-infections-physician-payer-forum-brazil-mexico-2015\/","title":{"rendered":"Hospital-Treated Infections | Physician &#038; Payer Forum | Brazil\/Mexico | 2015"},"content":{"rendered":"<p>The prevalence of difficult-to-treat infections is increasing worldwide, despite regional variations in the etiological pathogens. This report provides an extensive overview of the use of antibiotics in Brazil and Mexico, with a special focus on complicated hospital-treated infections (HTIs) due to methicillin-resistant Staphylococcus aureus (MRSA) and gram-negative pathogens. Such multi-drug resistant pathogens are becoming increasingly life-threatening and burdensome to local healthcare economies, which are overflowing with generics from a broad range of antibiotic classes. However, governments are keen to regulate the use of antibiotics so that forthcoming multi-drug resistance can be restrained. Healthcare providers struggle to employ more effective and costly antibiotics that address complicated infections caused by resistant pathogens in these cost-constrained markets. Thus, novel antibiotics, such as Actavis\/AstraZeneca\u2019s Avycaz, The Medicines Company\u2019s Carbavance, Tetraphase\u2019s eravacycline, and Merck\u2019s Zerbaxa, must overcome stringent clinical and reimbursement challenges.<\/p>\n","protected":false},"template":"","class_list":["post-391211","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hospital-treated-infections","biopharma-geography-brazil","biopharma-geography-mexico","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391211\/revisions"}],"predecessor-version":[{"id":576908,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391211\/revisions\/576908"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}